Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-27T19:51:59.949Z Has data issue: false hasContentIssue false

22 - Treatment of neuropathic pain

Published online by Cambridge University Press:  05 June 2012

Robert Fitridge
Affiliation:
University of Adelaide
Matthew Thompson
Affiliation:
St George's Hospital Medical School, London, UK
Stephan A Schug
Affiliation:
School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia
Kathryn JD Stannard
Affiliation:
School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia
Get access

Summary

INTRODUCTION

Neuropathic pain is defined by The International Association for the Study of pain (IASP) as pain following a primary lesion or dysfunction of the nervous system. It is caused either by peripheral damage with lesions involving peripheral nerves, dorsal root ganglia and the dorsal roots (peripheral neuropathic pain) or by central damage, which may involve injury caused by infarction or trauma of spinal cord or brain (central neuropathic pain).

Neuropathic pain results in persistent pain syndromes that have no biological function, but are difficult to treat and cause great distress to the individual. Neuropathic pain is also referred to as neurogenic pain, deafferentation pain, neuralgia, neuralgic pain and nerve pain.

Neuropathic pain may develop immediately after a nerve injury or after a variable interval. It may be maintained by factors different from the initial cause. It can persist for a long time and is frequently not explained by underlying pathology. Patients are frequently seen by many different specialists and their treatment often fails to resolve the pain. As the pain persists other factors such as environmental, psychological and social stressors become relevant contributors to the overall presentation.

PRINCIPLES OF TREATMENT

Treatment of neuropathic pain is not straightforward. The pain is often refractory to conventional analgesic regimens such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Opioids have only limited efficacy in neuropathic pain as outlined later in this chapter; therefore so called co-analgesics, medications which are not typically used as analgesics, are often the first-line treatment of neuropathic pain.

Type
Chapter
Information
Mechanisms of Vascular Disease
A Reference Book for Vascular Specialists
, pp. 401 - 422
Publisher: The University of Adelaide Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Treatment of neuropathic pain
    • By Stephan A Schug, School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia, Kathryn JD Stannard, School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia
  • Robert Fitridge, University of Adelaide, Matthew Thompson, St George's Hospital Medical School, London, UK
  • Book: Mechanisms of Vascular Disease
  • Online publication: 05 June 2012
  • Chapter DOI: https://doi.org/10.1017/UPO9781922064004.023
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Treatment of neuropathic pain
    • By Stephan A Schug, School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia, Kathryn JD Stannard, School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia
  • Robert Fitridge, University of Adelaide, Matthew Thompson, St George's Hospital Medical School, London, UK
  • Book: Mechanisms of Vascular Disease
  • Online publication: 05 June 2012
  • Chapter DOI: https://doi.org/10.1017/UPO9781922064004.023
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Treatment of neuropathic pain
    • By Stephan A Schug, School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia, Kathryn JD Stannard, School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia
  • Robert Fitridge, University of Adelaide, Matthew Thompson, St George's Hospital Medical School, London, UK
  • Book: Mechanisms of Vascular Disease
  • Online publication: 05 June 2012
  • Chapter DOI: https://doi.org/10.1017/UPO9781922064004.023
Available formats
×